Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

359 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, Kollef M, Menon A, Pogue JM, Shorr AF, Timsit JF, Zeitlinger M, Nagata TD. Wunderink RG, et al. Among authors: zeitlinger m. Lancet Infect Dis. 2021 Feb;21(2):213-225. doi: 10.1016/S1473-3099(20)30731-3. Epub 2020 Oct 12. Lancet Infect Dis. 2021. PMID: 33058798 Clinical Trial.
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.
Wressnigg N, Pöllabauer EM, Aichinger G, Portsmouth D, Löw-Baselli A, Fritsch S, Livey I, Crowe BA, Schwendinger M, Brühl P, Pilz A, Dvorak T, Singer J, Firth C, Luft B, Schmitt B, Zeitlinger M, Müller M, Kollaritsch H, Paulke-Korinek M, Esen M, Kremsner PG, Ehrlich HJ, Barrett PN. Wressnigg N, et al. Among authors: zeitlinger m. Lancet Infect Dis. 2013 Aug;13(8):680-9. doi: 10.1016/S1473-3099(13)70110-5. Epub 2013 May 10. Lancet Infect Dis. 2013. PMID: 23665341 Clinical Trial.
Extended infusion-putting the benefit into context.
Zeitlinger M. Zeitlinger M. Lancet Infect Dis. 2018 Apr;18(4):380-381. doi: 10.1016/S1473-3099(18)30115-4. Epub 2018 Mar 21. Lancet Infect Dis. 2018. PMID: 29582764 No abstract available.
A pragmatic trial in bone and joint infection.
Zeitlinger M. Zeitlinger M. Lancet Infect Dis. 2019 Aug;19(8):804-805. doi: 10.1016/S1473-3099(19)30354-8. Lancet Infect Dis. 2019. PMID: 31345447 Clinical Trial. No abstract available.
All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies.
Lodise TP, Bassetti M, Ferrer R, Naas T, Niki Y, Paterson DL, Zeitlinger M, Echols R. Lodise TP, et al. Among authors: zeitlinger m. Expert Rev Anti Infect Ther. 2022 May;20(5):707-719. doi: 10.1080/14787210.2022.2020099. Epub 2022 Jan 12. Expert Rev Anti Infect Ther. 2022. PMID: 34937518 Review.
359 results